Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemo + PSCT for High-Risk/Recurrent Sarcoma
NCT00002601Phase 2Completed
- Sponsor
- City of Hope
- Start
- Sep 1994
- Primary completion
- Sep 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, ifosfamide, melphalan and Cisplatin micelle injection (HA132) in sarcoma, sponsored by City of Hope. Primary endpoints: Feasibility of sequential high-dose chemotherapy, Number of Participants With Grade 3 Bilirubin at 2 years and 1 more. Started Sep 1994; status: completed.
02
Drugs
pegylated liposomal doxorubicinifosfamidemelphalanCisplatin micelle injection (HA132)
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT00002601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002601.